Drug Profile
XT 150
Alternative Names: IL-10 transgene plasmid DNA; XT 101; XT-101-R; XT-150Latest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator Xalud Therapeutics
- Class Anti-inflammatories; Antirheumatics; Eye disorder therapies; Gene therapies; Non-opioid analgesics; Skin disorder therapies
- Mechanism of Action Gene transference; Interleukin-10 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Musculoskeletal pain
- Preclinical Amyotrophic lateral sclerosis; Eye disorders; Gastrointestinal disorders; Multiple sclerosis; Skin disorders
- Research Unspecified
- No development reported Neuropathic pain
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in Neuropathic-pain in Australia (Intrathecal, Injection)
- 10 Nov 2023 Efficacy data from the phase II trial in Pain presented at the ACR Convergence 2023 (ACR-2023)
- 10 Nov 2023 Adverse events data from the phase II trial in Pain presented at the ACR Convergence 2023 (ACR-2023)